Torisel® (everolimus)
Everolimus is a mammalian target of rapamycin (mTOR) inhibitor that blocks cell proliferation and angiogenesis. It’s approved in many countries for several indications, most commonly for certain cancers and for preventing transplant rejection.
---
Key Uses
| Indication | Typical Use | Common Dosage |
|------------|-------------|---------------|
| Renal cell carcinoma (RCC) – advanced or metastatic | Oral therapy | 10 mg daily (adjusted for tolerability) |
| Subependymal giant cell astrocytoma (SEGA) in tuberous sclerosis complex (TSC) | Oral therapy | 2 mg daily (or 0.5 mg/kg for children) |
| Hormone‑receptor‑positive breast cancer (post‑chemotherapy, ER‑positive/HER2‑negative) | Oral therapy | 2.5–5 mg daily |
| Efficacy‑enhancing agent in combination regimens for certain solid tumors | Oral | Same as monotherapy, but in combos dose may be lower |
| Pre‑emptive treatment of organ‑transplant rejection (e.g., kidney, liver) | Oral | 1–5 mg daily (titrated) |
Always follow the prescribing information for your specific indication.
---
How it Works
Everolimus binds FKBP12, forming a complex that inhibits mTORC1, a key regulator of cell growth, proliferation, and protein synthesis. By blocking this pathway, the drug reduces tumor cell growth and angiogenesis.
---
Administration Tips
- Take with food to improve absorption (especially important for SEGA dosing in children).
- Swallow whole; do not crush or chew tablets.
- Monitor kidney and liver function before starting and periodically thereafter.
- Watch for signs of infection; everolimus can impair immune responses.
---
Common Side Effects
| System | Symptoms | Frequency | Management |
|--------|----------|-----------|------------|
| Gastrointestinal | Nausea, diarrhea, mouth sores | 20‑30 % | Antiemetics, anti‑diarrheal agents, hydration |
| Pulmonary | Interstitial lung disease, cough | <10 % | Pulmonary function tests, CT scan; discontinue if severe |
| Hematologic | Anemia, thrombocytopenia, leukopenia | 10‑15 % | CBC monitoring, dose hold/reduction |
| Metabolic | Hyperlipidemia, hyperglycemia | 10‑20 % | Lipid panel, glucose checks, diet changes |
| Dermatologic | Acne, rash, mouth ulcers | 10‑15 % | Topical steroids, antihistamines |
| Infection | Increased susceptibility | Variable | Prophylactic antivirals/antifungals in high‑risk pts |
If you experience severe symptoms (e.g., shortness of breath, fever, unexplained bleeding, or signs of infection), seek medical help promptly.
---
Contraindications & Precautions
| Condition | Reason |
|-----------|--------|
| Active uncontrolled infection | Immunosuppression increases risk |
| Known hypersensitivity to everolimus or components | Anaphylaxis risk |
| Severe renal or hepatic impairment | Drug metabolized by liver; renal clearance affected |
| Pregnancy | Teratogenic – use effective contraception in men & women of childbearing age |
| Concurrent use of strong CYP3A4 inhibitors/inducers | May raise or lower everolimus levels dramatically |
| Recent organ transplant (without physician’s guidance) | Risk of acute rejection |
Drug interactions:
- CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) → increase blood levels → ↑ toxicity.
- CYP3A4 inducers (e.g., rifampin, carbamazepine) → lower levels → ↓ efficacy.
- Concomitant immunosuppressants (cyclosporine, tacrolimus) → additive immunosuppression and altered drug levels.
---
Monitoring
1. Baseline: CBC, CMP, lipid panel, fasting glucose, creatinine clearance, chest X‑ray (if risk for ILD).
2. Periodic: CBC & CMP every 2–4 weeks initially, then every 3–6 months once stable.
3. Drug level: Therapeutic drug monitoring (TDM) may be used in transplant pts or when adverse events occur; target trough 5–15 ng/mL (varies by indication).
4. Imaging: Tumor response assessed by RECIST criteria (CT/MRI) every 8–12 weeks.
---
Stopping & Dose Adjustments
- Hold the drug if severe toxicity occurs (e.g., grade 3/4 cytopenias, pneumonitis).
- Reduce dose if moderate toxicity persists after a hold.
- Re‑initiate once toxicity resolves to ≤ grade 1.
- Permanent discontinuation may be required for severe, refractory side effects or organ toxicity.
---
Patient Advice
- Keep a medication diary: dose, timing, side effects.
- Stay hydrated and maintain a balanced diet.
- Report infections (fever, cough, sore throat) promptly.
- Avoid live vaccines while on everolimus.
- Use barrier protection for sex; discuss pregnancy plans with your provider.
- Do not stop abruptly; taper under supervision if advised.
---
Quick Reference
| Question | Answer |
|----------|--------|
| What does Torisel do? | It blocks mTOR signaling, slowing tumor growth and reducing angiogenesis. |
| Is it safe during pregnancy? | No—avoid. Use contraception. |
| Can I take it with other meds? | Many interactions; check with your clinician or pharmacist. |
| What’s the most serious risk? | Pneumonitis (interstitial lung disease) and infections. |
| How often should I check labs? | Initially every 2–4 weeks, then every 3–6 months. |
| Can I miss a dose? | Try to take at the same time daily; if a dose is missed, take it as soon as remembered unless it’s close to the next dose. |
---
Bottom line:
Torisel is a powerful drug that can help manage serious cancers and certain genetic conditions. Its benefits are significant, but it requires diligent monitoring and care to keep side effects manageable. If you have specific concerns—like drug interactions with your current regimen, dosing in kidney disease, or managing a particular side effect—talk with your oncologist, transplant team, or pharmacist. They can tailor the plan to your individual health status.
(The information above is for educational purposes and not a substitute for personalized medical advice. Always consult a qualified healthcare professional for your treatment decisions.)